Shrier Wealth Management LLC Buys Shares of 14,244 Gilead Sciences, Inc. $GILD

Shrier Wealth Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 14,244 shares of the biopharmaceutical company’s stock, valued at approximately $1,748,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Trivium Point Advisory LLC grew its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares during the last quarter. Binnacle Investments Inc lifted its stake in Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares during the last quarter. Hemington Wealth Management lifted its stake in Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares during the last quarter. Ignite Planners LLC boosted its position in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after buying an additional 86 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of Gilead Sciences by 0.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after buying an additional 87 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the chief financial officer owned 179,191 shares in the company, valued at $25,844,717.93. This represents a 1.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 299,280 shares of company stock valued at $42,820,550. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $139.37 on Wednesday. The firm has a market cap of $172.99 billion, a PE ratio of 20.59, a price-to-earnings-growth ratio of 1.79 and a beta of 0.37. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The business’s 50 day moving average price is $144.62 and its two-hundred day moving average price is $129.06. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a $0.82 dividend. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 48.45%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GILD. Leerink Partners upped their price target on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Oppenheimer boosted their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Scotiabank upped their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, TD Cowen lifted their price target on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.